Does LUTETIUM LU-177 VIPIVOTIDE TETRAXETAN Cause Malignant neoplasm progression? 251 Reports in FDA Database

Q: Does LUTETIUM LU-177 VIPIVOTIDE TETRAXETAN cause Malignant neoplasm progression?

251 reports of Malignant neoplasm progression have been filed with the FDA for LUTETIUM LU-177 VIPIVOTIDE TETRAXETAN, representing 2.3% of all LUTETIUM LU-177 VIPIVOTIDE TETRAXETAN adverse event reports.

Q: How dangerous is Malignant neoplasm progression from LUTETIUM LU-177 VIPIVOTIDE TETRAXETAN?

Of 251 reports, 81 (32.3%) resulted in death and 47 required hospitalization.

Prostate Health & Male Vitality — Naturally

ProstaVive: better flow, better sleep, better energy. 180-day guarantee.

Learn More

According to the FDA Adverse Event Reporting System (FAERS), 251 reports of Malignant neoplasm progression have been filed in association with LUTETIUM LU-177 VIPIVOTIDE TETRAXETAN (PLUVICTO). This represents 2.3% of all adverse event reports for LUTETIUM LU-177 VIPIVOTIDE TETRAXETAN.

251

Reports of Malignant neoplasm progression with LUTETIUM LU-177 VIPIVOTIDE TETRAXETAN

2.3%

of all LUTETIUM LU-177 VIPIVOTIDE TETRAXETAN reports

Deaths

Hospitalizations

How Dangerous Is Malignant neoplasm progression From LUTETIUM LU-177 VIPIVOTIDE TETRAXETAN?

Of the 251 reports, 81 (32.3%) resulted in death, 47 (18.7%) required hospitalization, and 2 (0.8%) were considered life-threatening.

Is Malignant neoplasm progression Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for LUTETIUM LU-177 VIPIVOTIDE TETRAXETAN. However, 251 reports have been filed with the FAERS database.

What Other Side Effects Does LUTETIUM LU-177 VIPIVOTIDE TETRAXETAN Cause?

General physical health deterioration (4,332) Ill-defined disorder (3,600) Death (1,179) Disease progression (286) Laboratory test abnormal (233) Prostatic specific antigen increased (212) Fatigue (177) Anaemia (154) Covid-19 (139) Platelet count decreased (130)

What Other Drugs Cause Malignant neoplasm progression?

PEMBROLIZUMAB (10,111) NIVOLUMAB (9,363) ENZALUTAMIDE (4,696) CARBOPLATIN (4,177) EVEROLIMUS (3,789) PACLITAXEL (3,484) LETROZOLE (3,445) IPILIMUMAB (3,296) FULVESTRANT (3,221) LENVATINIB (2,929)

Which LUTETIUM LU-177 VIPIVOTIDE TETRAXETAN Alternatives Have Lower Malignant neoplasm progression Risk?

LUTETIUM LU-177 VIPIVOTIDE TETRAXETAN vs LUTETIUM OXODOTREOTIDE LU-177 LUTETIUM LU-177 VIPIVOTIDE TETRAXETAN vs LUTROPIN ALFA LUTETIUM LU-177 VIPIVOTIDE TETRAXETAN vs LYMECYCLINE LUTETIUM LU-177 VIPIVOTIDE TETRAXETAN vs LYRICA LUTETIUM LU-177 VIPIVOTIDE TETRAXETAN vs LYSERGIDE

LUTETIUM LU-177 VIPIVOTIDE TETRAXETAN Full Profile All Malignant neoplasm progression Reports All Drugs Causing Malignant neoplasm progression LUTETIUM LU-177 VIPIVOTIDE TETRAXETAN Demographics